期刊文献+

脑脊液中Tau蛋白及Aβ检测对老年期痴呆早期诊断的意义 被引量:2

Diagnostic Value of Tau and Aain Cerebrospinal Fluid in Senile Dementia
下载PDF
导出
摘要 目的:探讨脑脊液(cerebrospinalfluid,CSF)中Tau蛋白及β-淀粉样蛋白(β-amyloidprotein,Aβ)对老年期痴呆(seniledementia,SD)主要包括老年性痴呆(Alzheimer'sdisease,AD)及脑血管病性痴呆(vasculardementia,VD)的诊断价值。方法:采用双抗体夹心酶联免疫吸附法(ELISA)检测54例AD患者,43例VD患者及30例正常对照者(normalcontrols,NC)脑脊液中Tau蛋白及Aβ1-42浓度。结果:老年期痴呆患者CSF中;①Tau蛋白浓度高于正常对照者(P<0.05);②Aβ1-42浓度低于正常对照者(P<0.05);③根据CSF中Tau蛋白、Aβ1-42浓度检测诊断老年期痴呆的灵敏度分别为51.55%、45.36%;特异性分别为90.90%、93.62%;结合Tau蛋白浓度及Aβ1-42浓度诊断SD的灵敏度为74.23%,特异性为93.33%。结论:临床上检测CSF中Tau蛋白、Aβ1-42浓度可作为早期诊断老年期痴呆的辅助指标。 Objective:To study the value of diagnosis on senile dementia i nclu ding Alzheimer's disease (AD) and vascular dementia(VD) by detecting Tau and a -amyloid protein(Aa) in senile dementia patients. Methods:The cerebrospinal f luid (CSF) levels of Tau and Aa1-42 in 54 patients with AD, 43 patients with V D and 30 normal controls (NC) were analyzed by sensitive enzyme-linked immunoso rbent assays (ELISA). Results:①The Tau levels in CSF of senile dementia are in creased compared with NC group. ②The Aa1-42 levels in CSF of senile dementia are decreased compared with NC group. ③By detecting the Tau concentrations and the Aa1-42 concentrations in CSF, the sensitivity of senile dementia is (51.55 %) and (45.36%) respectively, the specificity of senile dementia is (90.90%) and (93.62%) respectively; and the sensitivity and specificity of senile dement ia is 74.23%and 93.33%for combination of detection of Tau and Aa1-42 concent rations in CSF. Conclusion: The study suggests that the Tau levels and Aa1-42 in CSF are some potential diagnostic markers of senile dementia.
出处 《南京医科大学学报(自然科学版)》 CAS CSCD 北大核心 2004年第1期69-71,共3页 Journal of Nanjing Medical University(Natural Sciences)
基金 国家人事部回国人员基金资助项目(1998-58)
关键词 老年期痴呆 脑脊液 TAU蛋白 Β-淀粉样蛋白 senile dementia cerebrospinal fluid (CSF) Tau a-amyloid pro tein(Aa)
  • 相关文献

参考文献10

  • 1丁新生,程虹,王琨,王颖,姚娟,邓晓萱,董海蓉,宋正权.ELISA检测老年期痴呆脑脊液淀粉样蛋白β_(1-42)[J].临床检验杂志,2000,18(1):4-5. 被引量:6
  • 2朱明伟,汤洪川,王鲁宁.老年期痴呆的脑CT与病理研究[J].中国神经精神疾病杂志,1997,23(5):292-294. 被引量:16
  • 3王琨,丁新生,程虹,沈霞,姚娟,邓晓萱.老年期痴呆患者脑脊液微管相关蛋白tau的检测[J].临床神经病学杂志,2000,13(3):182-183. 被引量:4
  • 4Kanai M, Matsubara E, Isoe K, et al. Longitudinal study of cerebrospinal fluid levels of Tau, AI31-40, and Aβ1-42(43) in Alzheimer's Disease: A study in Japan[J] . Ann Neurol, 1998, 44(1): 17 -26.
  • 5Nishimura T, Takada M, Nakamura Y, et al. Basic and clinical study on the measurement of tau protein in cerebrospinal fluid as a biological marker for Alzhelmer' s disease and related disorders: multicenter study in Japan[J].Methods-Find-Exp-Clin-Pharmarcol, 1998, 20(3): 227 - 235.
  • 6Skoog I, Vanmechelen E, Andreasson LA, et al. A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: relation to severity of dementia and cerebral atrophy, but no to the apolipoprotein E4 allele [J]. Neurodegeneration, 1995, 4(4): 433 - 442.
  • 7Shoji M, Matsubara E, Kanai M, et al. Combination assay of CSF tau, A beta1-40 and A betal-42(43) as a bio-chemical marker of Alzheimer' s disease[J] . J Neurol Sci, 1998, 158(2): 134 - 140.
  • 8Marx J. Boring on β-amyloid role in Alzheimer' s disease[J]. Science, 1992, 255:688 - 689.
  • 9Motter R, Vigo Pelfrey C, Kholodenko D, et al. Reduction of β-amyloid Peptide42 in the cerebrospinal fluid of patintes with Alzeimer' s disease[J]. Ann Neurol, 1995,38(4):643 -648.
  • 10Andreasen N, Hesse C, Davidsson P, et al. Cerebrospinal fluid βamyloid[1-42] in Alzheimer disease: differences between early-and late-onset Alzheimer disease and stability during the course of disease[J]. Arch Neurol, 1999, 56(6):673 - 680.

二级参考文献19

共引文献21

同被引文献20

  • 1XIEGui-qin SUNXiu-lan TIANSu-ping CHENQi-sheng.Preventive Effects of Rhodosin and Melatonin from Damage Induced by β-Amyloid1-40 in Senile Rats[J].Journal of Nanjing Medical University,2004,18(4):203-206. 被引量:6
  • 2Grundman M, Petersen RC, Ferris SH, et al. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials[J]. Arch Neurol, 2004,61:59.
  • 3Borroni B,Rozzini L, Broglio L, et al.Platelet amyloid precursor protein abnormalities in mild congnitive impairment predict conversion to dementia of Alzheimer type[J]. Arch Neurol,2003,60:1740.
  • 4Emre M,Hanagasi HA. Evidence-based pharmacological treatment of dementia[J]. Eur J Neuro,2000, 7: 247.
  • 5Mackenzis IR,Moons DG. Nonsteroid anti-in-flammatory drug use and Alzheimer-type pathology in aging[J].Neurology, 1998,50: 986.
  • 6Tierney MC, Fisher RH, Lewis AJ,et al. The NINCDS-ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer's disease : A clinic-pathologic study of 57 cases[J]. Neurology, 1988, 38:359.
  • 7Blacker D, A lbertM S, Bassett SS, et al. Reliability and validity of NINCDS-ADRDA criteria for Alzheimar's disease[J] . Arch Neuro, 1994, 51: 1198.
  • 8Morris JC, Heyman A, Mohs RC, et al. The consortium to a registry for Alzheimer's disease part Ⅰ. Clinical and neuropsychological assessment of Alzheimer's disease[J]. Neurology, 1989, 39:1159.
  • 9Palmer K, Bckman L, Winblad B, et al. Detection of Alzheimer's disease and dementia in the preclinical phase: population based cohort study[J]. BMJ,2003,326:245.
  • 10Chui H. Reaching a diagnosis of a dementia subtype. In: Qizilbash N, ed. Evidence-based dementia practice[M]. Oxford, England: Blackwell Science, 2002.106.

引证文献2

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部